Tiomolibdate diammonium | Ammonium tetrathiomolybdate | CAS#15060-55-6 | 16330-92-0 | SOD1 inhibitor

MedKoo Cat#: 206752 | Name: Tiomolibdate diammonium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tiomolibdate diammonium, also known as Ammonium tetrathiomolybdate, is a SOD1 inhibitor with potential antiangiogenic and antitumor activities. ammonium Tiomolibdate diammonium has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.

Chemical Structure

Tiomolibdate diammonium

CAS#15060-55-6

Theoretical Analysis

MedKoo Cat#: 206752

Name: Tiomolibdate diammonium

CAS#: 15060-55-6

Chemical Formula: H8MoN2S4

Exact Mass: 261.8624

Molecular Weight: 260.28

Elemental Analysis: H, 3.10; Mo, 36.87; N, 10.76; S, 49.27

Price and Availability

Size	Price	Availability
1g	USD 150.00	Ready to ship
2g	USD 250.00	Ready to ship
5g	USD 450.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Tiomolibdate diammonium; Ammonium molybdenum sulfide; Ammonium tetrathiomolybdate; ATTM; Coprexa; NSC 286644; Thiomolybdic acid, diammonium salt

IUPAC/Chemical Name

Ammonium tetrathiomolybdate

InChi Key

PQNOIAHNKHBLRN-UHFFFAOYSA-P

InChi Code

InChI=1S/Mo.2H3N.4S/h;2*1H3;;;;/q;;;;;2*-1/p+2

SMILES Code

[S-][Mo]([S-])(=S)=S.[NH4+].[NH4+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# S9G10M14

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Tiomolibdate diammonium is a SOD1 inhibitor.

In vitro activity:

The target specificity of tetrathiomolybdate (ATM), an anti-angiogenic, anti-tumor agent against the viability / proliferation of arterial, venous, capillary endothelial and tumor cells was evaluated. Venous proliferation showed high ATM sensitivity (50% reduction ~ > or =5 uM ATM, p<0.01), capillary proliferation was inhibited > or =10 uM (p<0.05). Arterial endothelium were less sensitive to ATM, (50% inhibition ~ > or = 20 uM, p<0.01). YPEN-1 were inhibited >50 uM ATM. Capillary viability was inhibited > or =20 microM ATM (p<0.01); venous, arterial and tumor viability show less ATM sensitivity. These data suggest that venous and capillary endothelial proliferation are important targets in ATM therapy, but that other vascular segments and tumor cells may be less influenced. Reference: Inflamm Res. 2007 Dec;56(12):515-9. https://link.springer.com/article/10.1007%2Fs00011-007-7025-2

In vivo activity:

Ammonium tetrathiomolybdate (TTM) is a copper-chelating drug that is capable of removing a copper ion from copper-thiolate clusters, such as SOD1. TTM exerted therapeutic benefits in a mouse model of familial ALS (SOD1(G93A)). TTM treatment significantly delayed disease onset, slowed disease progression and prolonged survival by approximately 20%, 42% and 25%, respectively. TTM also effectively depressed the spinal copper ion level and inhibited lipid peroxidation, with a significant suppression of SOD1 enzymatic activity in SOD1(G93A). These results support the hypothesis that aberrant copper chemistry through a cysteine residue plays a critical role in mutant SOD1 toxicity and that TTM may be a promising therapy for familial ALS with SOD1 mutants. Reference: Exp Neurol. 2008 Sep;213(1):122-8. https://www.sciencedirect.com/science/article/abs/pii/S0014488608002197?via%3Dihub

Preparing Stock Solutions

The following data is based on the product molecular weight 260.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Carpenter A, Rassam A, Jennings MH, Robinson-Jackson S, Alexander JS, Erkuran-Yilmaz C. Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells. Inflamm Res. 2007 Dec;56(12):515-9. doi: 10.1007/s00011-007-7025-2. PMID: 18210236. 2. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, Ito Y, Suzuki T. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol. 2008 Sep;213(1):122-8. doi: 10.1016/j.expneurol.2008.05.011. Epub 2008 May 23. PMID: 18617166.

In vitro protocol:

In vivo protocol:

1. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, Ito Y, Suzuki T. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol. 2008 Sep;213(1):122-8. doi: 10.1016/j.expneurol.2008.05.011. Epub 2008 May 23. PMID: 18617166.

1: Chisholm CL, Wang H, Wong AH, Vazquez-Ortiz G, Chen W, Xu X, Deng CX. Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. Oncotarget. 2016 Oct 31. doi: 10.18632/oncotarget.12992. [Epub ahead of print] PubMed PMID: 27806319. 2: Xu S, Yang CT, Meng FH, Pacheco A, Chen L, Xian M. Ammonium tetrathiomolybdate as a water-soluble and slow-release hydrogen sulfide donor. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1585-8. doi: 10.1016/j.bmcl.2016.02.005. PubMed PMID: 26898812; PubMed Central PMCID: PMC4775341. 3: Chan CM, Langlois DK, Buchweitz JP, Lehner AF, Olivier NB, Herdt TH, Bailie MB, Schall WD. Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration to healthy dogs. Am J Vet Res. 2015 May;76(5):445-53. doi: 10.2460/ajvr.76.5.445. PubMed PMID: 25909377. 4: Chatterjee S, Sengupta K, Dey S, Dey A. Ammonium tetrathiomolybdate: a versatile catalyst for hydrogen evolution reaction from water under ambient and hostile conditions. Inorg Chem. 2013 Dec 16;52(24):14168-77. doi: 10.1021/ic402056k. PubMed PMID: 24261567. 5: Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, Ito Y, Suzuki T. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol. 2008 Sep;213(1):122-8. doi: 10.1016/j.expneurol.2008.05.011. PubMed PMID: 18617166. 6: Carpenter A, Rassam A, Jennings MH, Robinson-Jackson S, Alexander JS, Erkuran-Yilmaz C. Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells. Inflamm Res. 2007 Dec;56(12):515-9. doi: 10.1007/s00011-007-7025-2. PubMed PMID: 18210236. 7: Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006 Apr;63(4):521-7. PubMed PMID: 16606763. 8: Park KH, Park YD, Lee JR, Hahn HS, Lee SJ, Bae CD, Yang JM, Kim DE, Hahn MJ. Inhibition kinetics of mushroom tyrosinase by copper-chelating ammonium tetrathiomolybdate. Biochim Biophys Acta. 2005 Oct 30;1726(1):115-20. PubMed PMID: 16039066. 9: Haywood S, Dincer Z, Jasani B, Loughran MJ. Molybdenum-associated pituitary endocrinopathy in sheep treated with ammonium tetrathiomolybdate. J Comp Pathol. 2004 Jan;130(1):21-31. PubMed PMID: 14693121. 10: Kendall NR, Marsters P, Scaramuzzi RJ, Campbell BK. Expression of lysyl oxidase and effect of copper chloride and ammonium tetrathiomolybdate on bovine ovarian follicle granulosa cells cultured in serum-free media. Reproduction. 2003 May;125(5):657-65. PubMed PMID: 12713428. 11: Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003 Mar;60(3):379-85. PubMed PMID: 12633149. 12: Haywood S, Dincer Z, Holding J, Parry NM. Metal (molybdenum, copper) accumulation and retention in brain, pituitary and other organs of ammonium tetrathiomolybdate-treated sheep. Br J Nutr. 1998 Apr;79(4):329-31. PubMed PMID: 9624223. 13: Karunajeewa H, Wall A, Metz J, Grigg A. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust N Z J Med. 1998 Apr;28(2):215-6. PubMed PMID: 9612534. 14: Ayiannidis A, Giroussi S, Voulgaropoulos A. Aspects of protein bound copper in sheep plasma and its release in vitro especially after treatment with ammonium tetrathiomolybdate. J Trace Elem Med Biol. 1996 Dec;10(4):245-50. PubMed PMID: 9021676. 15: Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996 Oct;53(10):1017-25. PubMed PMID: 8859064. 16: Botha CJ, Swan GE, Minnaar PP. Pharmacokinetics of ammonium tetrathiomolybdate following intravenous administration in sheep. J S Afr Vet Assoc. 1995 Mar;66(1):6-10. PubMed PMID: 7629788. 17: Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol. 1994 Jun;51(6):545-54. PubMed PMID: 8198464. 18: Kincaid RL, White CL. The effects of ammonium tetrathiomolybdate intake on tissue copper and molybdenum in pregnant ewes and lambs. J Anim Sci. 1988 Dec;66(12):3252-8. PubMed PMID: 3230085. 19: Humphries WR, Morrice PC, Bremner I. A convenient method for the treatment of chronic copper poisoning in sheep using subcutaneous ammonium tetrathiomolybdate. Vet Rec. 1988 Jul 9;123(2):51-3. PubMed PMID: 3413942. 20: Humphries WR, Mills CF, Greig A, Roberts L, Inglis D, Halliday GJ. Use of ammonium tetrathiomolybdate in the treatment of copper poisoning in sheep. Vet Rec. 1986 Dec 13;119(24):596-8. PubMed PMID: 3811176.